Published in J Clin Microbiol on February 01, 1996
Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990s. Clin Microbiol Rev (2003) 3.52
Variability in 3' end of 16S rRNA sequence of Mycobacterium ulcerans is related to geographic origin of isolates. J Clin Microbiol (1996) 3.07
Lymphadenitis in children is caused by Mycobacterium avium hominissuis and not related to 'bird tuberculosis'. Eur J Clin Microbiol Infect Dis (2008) 1.08
Mycobacterium genavense infections in pet animals. J Clin Microbiol (1996) 1.02
First detection of mycobacteria in African rodents and insectivores, using stratified pool screening. Appl Environ Microbiol (2007) 1.02
Disseminated infection with Mycobacterium genavense: a challenge to physicians and mycobacteriologists. J Clin Microbiol (1999) 0.99
The environmental pathogen Mycobacterium ulcerans grows in amphibian cells at low temperatures. Appl Environ Microbiol (2002) 0.93
Use of gas chromatographic fatty acid and mycolic acid cleavage product determination to differentiate among Mycobacterium genavense, Mycobacterium fortuitum, Mycobacterium simiae, and Mycobacterium tuberculosis. J Clin Microbiol (1998) 0.92
Microaerophilic conditions promote growth of Mycobacterium genavense. J Clin Microbiol (1998) 0.92
Mycobacterium genavense in AIDS patients, report of 24 cases in Italy and review of the literature. Eur J Epidemiol (1998) 0.89
Mycobacterium genavense Infections in a Tertiary Hospital and Reviewed Cases in Non-HIV Patients. Patholog Res Int (2014) 0.86
Detection of fastidious mycobacteria in human intestines by the polymerase chain reaction. Eur J Clin Microbiol Infect Dis (1997) 0.84
Standardized BACTEC method to measure clarithromycin susceptibility of Mycobacterium genavense. J Clin Microbiol (1998) 0.81
Mycobacterium tuberculosis infection in a green-winged macaw (Ara chloroptera): report with public health implications. J Clin Microbiol (1998) 0.79
Concurrent atypical diffused tuberculosis and macrorhabdosis in a canary (Serinus canaria). Vet Res Forum (2015) 0.75
Experimental inoculation of BFDV-positive budgerigars (Melopsittacus undulatus) with two Mycobacterium avium subsp. avium isolates. Biomed Res Int (2014) 0.75
Rapid and simple method for purification of nucleic acids. J Clin Microbiol (1990) 44.73
Complete nucleotide sequence of a 16S ribosomal RNA gene from Escherichia coli. Proc Natl Acad Sci U S A (1978) 32.65
Genotypic identification of mycobacteria by nucleic acid sequence determination: report of a 2-year experience in a clinical laboratory. J Clin Microbiol (1993) 9.76
Disseminated "Mycobacterium genavense" infection in patients with AIDS. Lancet (1992) 4.42
Epidemiology of mycobacterial diseases. Clin Dermatol (1996) 3.01
Fatal infection with a novel, unidentified mycobacterium in a man with the acquired immunodeficiency syndrome. N Engl J Med (1990) 2.54
Clinical and epidemiologic features of infection with Mycobacterium genavense. Swiss HIV Cohort Study. Arch Intern Med (1995) 1.95
Mycobacterium genavense sp. nov. Int J Syst Bacteriol (1993) 1.88
Laboratory aspects of "Mycobacterium genavense," a proposed species isolated from AIDS patients. J Clin Microbiol (1992) 1.82
Selective isolation of mycobacteria from soil: a statistical analysis approach. J Gen Microbiol (1988) 1.62
Mycobacteriosis due to Mycobacterium genavense in six pet birds. J Clin Microbiol (1993) 1.49
Infection with a fastidious Mycobacterium resembling Mycobacterium simiae in seven patients with AIDS. Ann Intern Med (1992) 1.27
Disseminated Mycobacterium genavense infection: clinical and microbiological features and response to therapy. AIDS (1993) 1.19
Invasive infection with Mycobacterium genavense in three children with the acquired immunodeficiency syndrome. Eur J Clin Microbiol Infect Dis (1993) 1.13
Finding the "hidden positive" in tuberculosis eradication programs. The role of the sensitive trisodium phosphate-benzalkonium (zephiran) culture technique. Am Rev Respir Dis (1962) 1.10
Species-specific Mycobacterium genavense DNA in intestinal tissues of individuals not infected with human immunodeficiency virus. J Clin Microbiol (1995) 1.09
Mycobacterium genavense infection presenting as a solitary brain mass in a patient with AIDS: case report and review. Clin Infect Dis (1994) 1.07
Mycobacterium genavense. Autopsy findings in three patients. Am J Clin Pathol (1994) 1.01
Cervical lymphadenitis caused by a fastidious mycobacterium closely related to Mycobacterium genavense in an apparently immunocompetent woman: diagnosis by culture-free microbiological methods. J Clin Microbiol (1995) 0.95
[AIDS and atypical mycobacteria]. Ann Soc Belg Med Trop (1987) 0.90
Disseminated Mycobacterium genavense infection in two patients with AIDS. Clin Infect Dis (1994) 0.88
Susceptibility of captive wildfowl to avian tuberculosis: the importance of genetic and environmental factors. Tubercle (1991) 0.79
Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet (2000) 5.49
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet (1999) 4.83
Insects in the transmission of Mycobacterium ulcerans infection. Lancet (1999) 4.46
Disseminated "Mycobacterium genavense" infection in patients with AIDS. Lancet (1992) 4.42
Effects of antibiotic treatment in the subset of common-cold patients who have bacteria in nasopharyngeal secretions. Lancet (1996) 4.22
Brief report: disseminated osteomyelitis from Mycobacterium ulcerans after a snakebite. N Engl J Med (1993) 3.75
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA (1999) 3.34
Turnover of CD4+ and CD8+ T lymphocytes in HIV-1 infection as measured by Ki-67 antigen. J Exp Med (1998) 3.24
Variability in 3' end of 16S rRNA sequence of Mycobacterium ulcerans is related to geographic origin of isolates. J Clin Microbiol (1996) 3.07
Epidemiology of mycobacterial diseases. Clin Dermatol (1996) 3.01
Mycobacterium ulcerans in wild animals. Rev Sci Tech (2001) 2.84
Fatal strongyloidiasis in immunosuppressed patients. Am J Med (1974) 2.76
Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections. J Infect Dis (1987) 2.71
Direct detection and identification of Mycobacterium ulcerans in clinical specimens by PCR and oligonucleotide-specific capture plate hybridization. J Clin Microbiol (1997) 2.50
Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS (2001) 2.42
16S rRNA sequence diversity in Mycobacterium celatum strains caused by presence of two different copies of 16S rRNA gene. J Clin Microbiol (1998) 2.33
Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis (2001) 2.24
Two different 16S rRNA genes in a mycobacterial strain. J Clin Microbiol (1996) 2.17
Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med (1999) 2.17
A cohort study of drug users' compliance with zidovudine treatment. Arch Intern Med (1994) 2.16
Cloning and analysis of the K1 capsule biosynthesis genes of Escherichia coli: lack of homology with Neisseria meningitidis group B DNA sequences. Infect Immun (1983) 2.15
Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV Med (2008) 2.03
[HIV epidemic: an end to exceptional regulation? Response to the article which appeared under this title in the Revue médicale de la Suisse romande (112, 239-241, 1991)]. Rev Med Suisse Romande (1992) 2.02
Treatment for cerebral toxoplasmosis protects against Pneumocystis carinii pneumonia in patients with AIDS. The Swiss HIV Cohort Study. Ann Intern Med (1991) 2.02
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet (2001) 2.01
Effective T-cell responses select human immunodeficiency virus mutants and slow disease progression. J Virol (2007) 1.98
Human Mycobacterium ulcerans infections developing at sites of trauma to skin. Am J Trop Med Hyg (1974) 1.89
Mycobacterium genavense sp. nov. Int J Syst Bacteriol (1993) 1.88
In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. Antimicrob Agents Chemother (1998) 1.80
Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis (1998) 1.72
Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Br J Cancer (2008) 1.70
Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother (1999) 1.69
Characterization of an unusual Mycobacterium: a possible missing link between Mycobacterium marinum and Mycobacterium ulcerans. J Clin Microbiol (2002) 1.67
Red fingers syndrome in patients with HIV and hepatitis C infection. Lancet (1996) 1.66
Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants. J Virol (1998) 1.65
[Buruli ulcer: risk of bone involvement! Apropos of 33 cases observed in Benin]. Med Trop (Mars) (2000) 1.63
Incidence of hepatitis C, hepatitis B and HIV infections among drug users in a methadone-maintenance programme. AIDS (1992) 1.55
Clinical relevance of cytomegalovirus viraemia(*,†). HIV Med (2011) 1.55
Isolation of mycobacteria from healthy persons' stools. Int J Lepr Other Mycobact Dis (1988) 1.55
The use of IS2404 restriction fragment length polymorphisms suggests the diversity of Mycobacterium ulcerans from different geographical areas. Am J Trop Med Hyg (2001) 1.54
Symptomatic primary infection due to human immunodeficiency virus type 1: review of 31 cases. Clin Infect Dis (1993) 1.52
Reasons for failure of prevention of Toxoplasma encephalitis. Swiss HIV Cohort Study. AIDS (1996) 1.52
Evaluation of PCR-restriction profile analysis and IS2404 restriction fragment length polymorphism and amplified fragment length polymorphism fingerprinting for identification and typing of Mycobacterium ulcerans and M. marinum. J Clin Microbiol (2001) 1.49
Mycobacterium ulcerans disease: role of age and gender in incidence and morbidity. Trop Med Int Health (2004) 1.48
Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease. Infect Immun (2004) 1.48
Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995. AIDS (1998) 1.46
A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. J Infect Dis (1999) 1.46
Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection. AIDS (2000) 1.44
[Mycobacterium ulcerans cutaneous infections: Buruli ulcers]. Med Trop (Mars) (1995) 1.44
Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. AIDS (1999) 1.44
Cytotoxic activity of Mycobacterium ulcerans. Infect Immun (1974) 1.42
Leprosy research and patient care over the past century. Int J Lepr Other Mycobact Dis (1998) 1.40
Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV Med (2006) 1.38
HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med (1997) 1.35
Immunosuppressive properties of the soluble toxin from Mycobacterium ulcerans. J Infect Dis (1988) 1.33
Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users. AIDS (1990) 1.33
Distribution of Mycobacterium ulcerans infections in Zaire, including the report of new foci. Ann Soc Belg Med Trop (1974) 1.23
Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study. Antivir Ther (2002) 1.19
Severity and prognosis of acute human immunodeficiency virus type 1 illness: a dose-response relationship. Clin Infect Dis (1998) 1.18
Association between the rate of CD4+ T cell decrease and the year of human immunodeficiency virus (HIV) type 1 seroconversion among persons enrolled in the Swiss HIV cohort study. J Infect Dis (1999) 1.17
Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006. HIV Med (2008) 1.16
Molecular basis for cross-reactivity between a strain of Mycobacterium terrae and DNA probes for Mycobacterium tuberculosis complex. Eur J Clin Microbiol Infect Dis (1995) 1.16
Assessment of a real-time PCR test to diagnose syphilis from diverse biological samples. Sex Transm Infect (2009) 1.15
Response of HIV RNA to didanosine as a predictive marker of survival. AIDS (1995) 1.15
Cell-associated HIV-1 RNA in blood as indicator of virus load in lymph nodes. The Swiss HIV Cohort Study. J Infect Dis (1999) 1.14
Heat treatment of Mycobacterium ulcerans infections without surgical excision. Am J Trop Med Hyg (1974) 1.14
Effect of oxygen on growth of Mycobacterium ulcerans in the BACTEC system. J Clin Microbiol (1998) 1.12
Quantitation of human immunodeficiency virus provirus and circulating virus: relationship with immunologic parameters. J Infect Dis (1992) 1.11
Toxoplasma encephalitis in patients with the acquired immunodeficiency syndrome. Medicine (Baltimore) (1992) 1.11
Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. The Swiss HIV Cohort Study. AIDS (2000) 1.10
Mycotic granuloma caused by Phialophora repens. Am J Clin Pathol (1975) 1.10
Experimental leprosy in three species of monkeys. Science (1985) 1.09
Species-specific Mycobacterium genavense DNA in intestinal tissues of individuals not infected with human immunodeficiency virus. J Clin Microbiol (1995) 1.09
Leprosy. JAMA (1982) 1.09
Prophylactic effect of mycobacterium bovis BCG vaccination against osteomyelitis in children with Mycobacterium ulcerans disease (Buruli Ulcer). Clin Diagn Lab Immunol (2002) 1.08
Causes of macrocytosis in HIV-infected patients not treated with zidovudine. Swiss HIV Cohort Study. J Infect (2000) 1.08
Leprosy--a zoonosis. Lepr Rev (1981) 1.08
Mycobacterium ulcerans infection in a child from Angola: diagnosis by direct detection and culture. Trop Med Int Health (1998) 1.06
[Disseminated infection with Mycobacterium celatum]. Schweiz Med Wochenschr (1996) 1.03
Chronic destructive lung disease associated with a novel mycobacterium. Am J Respir Crit Care Med (1994) 1.03
Depression of lymphocyte responses to mitogens in mangabeys with disseminated experimental leprosy. Cell Immunol (1985) 1.03
Prognostic value of viremia in patients with long-standing human immunodeficiency virus infection. Swiss HIV Cohort Study Group. J Infect Dis (1996) 1.02
Biochemical properties and fatty acid composition of Mycobacterium haemophilum: study of 16 isolates from Australian patients. J Clin Microbiol (1993) 1.02
Growth-deficient mycobacteria in patients with AIDS: diagnosis by analysis of DNA amplified from blood or tissue. Clin Infect Dis (1995) 1.02
Detection of phospholipase C in nontuberculous mycobacteria and its possible role in hemolytic activity. J Clin Microbiol (2001) 1.01
Incubation time of acute human immunodeficiency virus (HIV) infection and duration of acute HIV infection are independent prognostic factors of progression to AIDS. J Infect Dis (2000) 1.01
Cervical lymphadenitis caused by Mycobacterium genavense in a healthy child. Pediatr Infect Dis J (1996) 0.97
Detection of mycobacterial nucleic acids by polymerase chain reaction in fixed tissue specimens of patients with human immunodeficiency virus infection. Swiss HIV Cohort Study. Diagn Mol Pathol (1999) 0.97
Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily. J Antimicrob Chemother (2004) 0.97
Direct ex vivo analysis reveals distinct phenotypic patterns of HIV-specific CD8(+) T lymphocyte activation in response to therapeutic manipulation of virus load. Eur J Immunol (2001) 0.97
Blood and charcoal added to acidified agar media promote the growth of Mycobacterium genavense. Diagn Microbiol Infect Dis (1999) 0.97
Massive gastrointestinal hemorrhage from a diverticulum of the appendix. Dig Dis Sci (1980) 0.97